Prevalence of occult hepatitis B virus infection among patients receiving haemodialysis in Sana’a city

Bodoor Ali Hussen Al-Masoodi, Alariqi Reem, Saleh S.Bahaj, Raja M. Al-Haimi, Hassan A. Al-Shamahy, Nagib Abuasba, Abdu-Raof Mohammad Al-shawkany, Jay Prakash Prasad Kumal

Keywords:
HBV
Occult hepatitis B virus
Haemodialysis patients
Conventional PCR
Sana’a city

ABSTRACT

Background: Occult hepatitis B virus infection (OBI) is a challenging entity. Due to the increase in invasive procedures, blood transfusions, and difficulties in diagnosing OBI, patients are more likely to acquire OBI. This cross-sectional study was conducted to assess the prevalence of OBI by hepatitis B virus (HBV)-DNA detection, the prevalence of HBV infection by total hepatitis B core antibody (HBcAb) detection, and the potential risk factors for HBV infection in patients receiving haemodialysis regularly.

Methods: This study included 80 patients receiving haemodialysis regularly, without acute or chronic HBV infection. They were selected from the dialysis units in Sana’a city, Yemen from June 2016 to June 2017. Patients who were positive for hepatitis B surface antigen and hepatitis B surface antibody were excluded from this study. Blood samples were taken prior to each haemodialysis session, and serological markers of HBV were included. HBcAb was measured by enzyme-linked immunosorbent assay, and HBV-DNA was measured by polymerase chain reaction.

Results: HBV-DNA was detected in four patients (5%) and HBcAb was detected in 38 patients (47.5%). There was a significant association between HBV-DNA and HBcAb in patients receiving haemodialysis regularly.

Conclusions: Patients who test positive for HBcAb should undergo additional HBV-DNA testing to allow accurate HBV screening and prevent infection of other patients.

Introduction

Hepatitis is a general term indicating hepatic inflammation defined by inflammatory cells. Most cases of hepatitis are caused by a group of viruses known as the hepatitis viruses. Humans are the only reservoir of hepatitis B virus (HBV) (Gerlich et al., 2010). The incidence of HBV infection varies widely by geographic area. It is estimated that 350 million people are affected by HBV worldwide, which corresponds to a high rate of carriage of hepatitis B surface antigen (HBsAg) (up to 20%), particularly in South and East Asia (Allain, 2004). Previous data showed that hepatitis B is hyperendemic in Yemen, and infection with HBV and hepatitis C virus (HCV) is an important cause of chronic liver disease (Murad et al., 2013). Patients receiving haemodialysis have a higher risk of viral hepatitis, and viral hepatitis accounts for 1.9% of deaths (Abdel-Maksoud et al., 2019). HBV is a double-stranded DNA virus from the family Hepadnaviridae and the genus Orthohepadnavirus (Datta et al., 2012). There are three types of HBV infection: acute, chronic and occult (Nakamoto et al., 2014). Occult HBV infection (OBI) is characterized by the presence of hepatitis B virus deoxyribonucleic acid (HBV-DNA) in serum, or on liver biopsy in HBsAg-negative patients with or without previous serological markers virus exposure like (HBsAg), anti-hepatitis B core IgM antibody (anti-HBcIgM) and hepatitis B "e" antigen (HBeAg) (Coppola et al., 2015). HBV is highly contagious, with up to 30% chance of seroconversion. In contrast, the probabilities of infection with HCV and human immunodeficiency virus are 1.8% and 0.31%, respectively. Patients undergoing regular haemodialysis are at increased risk of contracting diseases via the parenteral route as they are immunosuppressed, undergo invasive treatment, respond poorly to the HBV vaccine, and require multiple blood transfusions, and also due to the duration of dialysis. The prevalence of OBI is unknown and is determined by the sensitivity of the HBsAg and DNA assays used. Endemic HBV infection is associated with OBI. Patients from areas where HBV is prevalent...
are more likely to develop OBI (Onorato et al., 2021). OBI can accelerate the progression of cirrhosis and hepatocellular cancer (Squadratto et al., 2014). If cirrhosis and hepatocellular carcinoma develop, reactivation occurs, leading to acute hepatitis which can be fatal (Song and Hwang, 2013). This study investigated patients receiving haemodialysis regularly in Sana’a city, Yemen in order to determine the prevalence of OBI by detecting HBV-DNA using conventional polymerase chain reaction (PCR), and to determine the prevalence of HBV infection by detecting hepatitis B core antibody (HBcAb).

Materials and methods

Subjects

This cross-sectional study was conducted on 80 patients with renal failure in haemodialysis units at Al Thawra Modern General Hospital and Al Jamhouri Teaching Hospital, Sana’a city from June 2016 to June 2017. Data on the medical history of each patient, including name, age, sex, address and duration of haemodialysis, were collected using a questionnaire. Patients who were HCV positive and HBsAg positive were excluded.

Specimen collection

Five millilitres of venous blood were drawn from each patient in the haemodialysis sessions, and the samples were divided into two parts, each labelled with patient name and serial number. The first part consisted of serum in a vacuum tube, which was separated from whole blood after being allowed to clot for 15 min, followed by centrifugation at 3000 rpm for 10 min. Thereafter, it was transferred to Eppendorf tubes with a pipette to detect HBsAg, HBcAb and total (T)-HBcAb. The second part consisted of 2 mL of whole blood placed in an EDTA tube for detection of HBV-DNA by conventional PCR.

Determination of HBcAb, HBsAb and T-HBcAb by ELISA

Enzyme-linked immunosorbent assays (ELISA) for HBsAg, HBcAb and T-HBcAb were performed in accordance with the test kits (ARCHITECT i 1000 SR System, Abbott Diagnostics, Abbott Park, IL, USA). HBcAb-positive samples were excluded from the study (patients receiving haemodialysis were selected according to the dialysis record in which they were HBcAb positive, and every patient separated from the other in the dialysis unit (Martinez et al., 2015).

Determination of HBV-DNA by conventional PCR

DNA extraction from whole blood

The AccuPrep Genomic DNA Extraction Kit (Cat. No: K-3032; Bioneer, Daejeon, South Korea) was used to extract DNA from all whole blood samples in accordance with the manufacturer’s instructions (Khour et al., 2017).

PCR amplification

The HBcAg gene was amplified using forward primer P1 (nt 2823-2845; 5’-TCA GCA TAT TCT TGG GAA CAA GA-3’) and reverse primer S1-2 (nt 685-704; 5’-CGA ACC ACT GAA CAA ATG GC-3’). For amplification, initial pre-denaturation was performed at 95°C for 5 min, followed by denaturation at 95°C for 30 s, primer annealing at 57°C for 30 s, elongation at 68°C for 80 s, and final extension at 68°C for 5 min. The sample was stored at 20°C until the following day for analysis. Template DNA and primers were added to the Accup tubes of the reaction mixture (DNA template 5 μL, forward primer 0.5 μL, reverse primer 0.5 μL, sample DNA 5 μL and PCR-grade water 14 μL). The lyophilized blue pellet dissolved completely, and was centrifuged with ExiSpin Vortex/Centrifuge for 15 s at high speed, followed by 5-s spins at 1500 rpm for four cycles (AccuPower ProFi Taq PCR PreMix, South Korea) (Rashid and Salih, 2015).

| Table 1 | Demographic characteristics of patients receiving haemodialysis in Sana’a city, 2016. |
|---------|-----------------------------------------------|
| Demographic characteristics | n   | %  |
| Age group (years) |       |     |
| < 20            | 5    | 6.2 |
| 20-40           | 31   | 38.8|
| 41-60           | 30   | 37.5|
| >60             | 14   | 17.5|
| Total           | 80   | 100 |
| Sex             |       |     |
| Male            | 43   | 53.8|
| Female          | 37   | 46.2|
| Total           | 80   | 100 |

* Mean ± standard deviation.

Electrophoresis of the amplified product

The PCR products were analysed by gel electrophoresis in 2% agarose gels in TBE buffer. Gels were run at 100 V for 40 min in 1X TAE containing 1 μl ethidium bromide. The PCR products were visualized with ultraviolet light (Figure 1). The bands were aligned at 1063 base pairs (bp) indicating a positive reaction (Rashid and Salih, 2015).

Statistical analysis

Collected data were encrypted and entered into SPSS Version 21 (IBM Corp., Armonk, NY, USA). Quantitative data were plotted as mean and standard deviation. The percentage of values for each category provided was quantified. Statistical comparison between categorical variables was performed using Chi-squared pair test, and P≤0.05 was considered to indicate significance.

Results

The sociodemographic variables of patients receiving haemodialysis are summarized in Table 1. Among the 80 patients, 38.8% (n=31) were aged 20–40 years, 37.5% (n=30) were aged 41–60 years, 17.5% (n=14) were aged >60 years, and 6.2% (n=5) were aged <20 years. Overall, 53.8% (n=43) of patients were male and 46.2% (n=37) were female.

- In terms of the prevalence of OBI, four of the eighty patients (5%) were HBV-DNA positive, and 76 (95%) were HBV-DNA negative (Figure 2).

The prevalence of OBI in patients receiving haemodialysis was 10.5% (n=4). None of these four patients had a negative HBCaB value. An association was found between the presence of HBV-DNA and T-HBcAb (Table 2).

Table 3 shows the risk factors for T-HBcAb and HBV-DNA infection in patients receiving haemodialysis. In patients receiving dialysis outside of what was specified (100%), surgical history (66.7%) with positive T-HBcAb, blood transfusion (54.2%) with positive T-HBcAb, and specified dialysis for 1 year (50%) and 1 year (16.7%) in positive T-HBcAb, the converged proportions were longer (Taha et al., 2013). They were found in patients with mix factors (50%) in HBCaB who had undergone dental treatments and had positive T-HBcAb (0%). While there were patients in family history of HBV, the HBCaB is (0%), and all risk factors of this study are statistically insignificant. As the abovementioned methods were used to spread HBV, they have been recognized as risk factors.

Discussion

OBI is receiving more attention due to its clinical relevance in the development of chronic liver disease, and its relationship with hepatocellular carcinoma is growing (Taha et al., 2013). Due to frequent invasive procedures, prolonged vascular access with high exposure to infected patients and contaminated equipment, a higher number of blood transfusions, a longer duration of dialysis and immunosuppression, patients receiving haemodialysis regularly are more likely to acquire OBI.
Figure 1. Electrophoresis of hepatitis B virus-DNA. Lane 1, ladder (100-500 +1000+1500+3000 bp); lane 2, positive control, lane 3, negative control; lanes 4, 5, 6 and 7, positive samples.

Figure 2. Prevalence of occult hepatitis B virus infection among patients in haemodialysis units in Sana’a city, 2016.

Table 2
Association of hepatitis B virus (HBV)-DNA with total hepatitis B core antibody (T-HBcAb) in patients receiving haemodialysis in Sana’a city, 2016.

| Characteristics | HBcAb | $\chi^2$ | OR | CI | P-value$^b$ |
|-----------------|-------|--------|----|----|------------|
|                 | Positive | Negative | Total | n  | %  | n  | %  | n  | %  | Lower | Upper |          |
| HBV-DNA assay   | Detected | 4 | 10.5 | 0 | 0 | 4 | 5 |  |  |  |  |  |
|                 | Not detected | 34 | 89.5 | 42 | 100 | 76 | 95 | 4.65 | 2.23 | 1.74 | 2.87 | 0.047 |

OR, odds ratio; CI, confidence interval.

$^a$ Fisher's exact test, $\chi^2\geq3.9$.

$^b$ $P\leq0.05$ was considered to indicate significance.
Table 3

Potential risk factors for contracting hepatitis B core antibody (HBcAb) in patients receiving haemodialysis in Sana’a, 2016.

| Characteristics                  | HBcAb positive | HBcAb negative | Chart 2 | OR   | CI Lower | CI Upper | P-value* |
|----------------------------------|----------------|----------------|---------|-------|----------|----------|----------|
| Duration of dialysis (years)     |                |                |         |       |          |          |          |
| <1                               | 1              | 16.7           | 5       | 83.3  | 2.47     | 0.20     | 0.22     | 1.79     | 0.20     |
| ≥1                               | 37             | 50             | 37      | 50    | 0.61     | 0.56     | 3.82     | 0.47     |
| Blood transfusion                |                |                |         |       |          |          |          |          |          |
| Yes                              | 13             | 54.2           | 11      | 45.8  | 0.62     | 0.27     | 0.19     | 26.1     | 0.60     |
| No                               | 25             | 44.6           | 31      | 55.4  | 0.38     | 0.20     | 1.58     | 2.50     | 0.11     |
| Surgical history                 |                |                |         |       |          |          |          |          |          |
| Yes                              | 2              | 66.7           | 1       | 33.3  | 1.16     | 2.13     | 1.68     | 2.70     | 0.47     |
| No                               | 36             | 46.8           | 41      | 53.2  | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |
| Dental procedure                 |                |                |         |       |          |          |          |          |          |
| Yes                              | 0              | 0              | 4       | 100   | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |
| No                               | 38             | 50             | 38      | 50    | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |
| Dialysis outside specified units |                |                |         |       |          |          |          |          |          |
| Yes                              | 1              | 100            | 0       | 0     | 1.16     | 2.13     | 1.68     | 2.70     | 0.47     |
| No                               | 37             | 46.8           | 42      | 53.2  | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |
| Family history                   |                |                |         |       |          |          |          |          |          |
| Yes                              | 0              | 0              | 0       | 0     | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |
| No                               | 38             | 47.7           | 42      | 52.5  | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |
| Mix factors                      |                |                |         |       |          |          |          |          |          |
| Yes                              | 21             | 50             | 21      | 50    | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |
| No                               | 17             | 44.7           | 21      | 55.3  | 0.55     | 1.11     | 0.46     | 2.67     | 0.82     |

OR, odds ratio; CI, confidence interval.

* Fisher’s exact test, \( \chi^2 \geq 3.9 \).

\( P \leq 0.05 \) was considered to indicate significance.

Than other patient who dont do the OBI test. Liver biopsies of patients receiving haemodialysis tend to be difficult to perform, and are not usually recommended. Therefore, most OBI diagnoses are based on blood test results (El-Ghitany et al., 2013). The prevalence of OBI ranges from <1% to 87% in patients in dialysis units. Due to the differing prevalence of HBV infection, and differing sensitivity and specificity of detection methods, the available data show that its prevalence of HBV infection varies between countries (Sharif-Mood et al., 2009). To the authors’ knowledge, in Yemen, only one study has been published on the number of people who had OBI with chronic liver disease, and the prevalence rate was 4.3% (Tabat et al., 2012). The present study is the first study to address this issue in the dialysis units of Sana’a city, and aimed to determine: (1) the prevalence of OBI in patients receiving haemodialysis by detecting HBV-DNA using a conventional PCR technique; (2) the prevalence of HBV infection in patients receiving haemodialysis by detecting T-HBcAb; and (3) the potential risk factors for HBV infection in patients receiving haemodialysis. Based on the detection of HBV-DNA, which is the gold standard test for OBI, this study found that the prevalence of OBI in patients receiving haemodialysis was 5%. This result is consistent with the rates in Western and Upper Egypt (6% and 4.1%, respectively) (Bedewy and Ibrahim, 2006), but higher than the rates in Tehran, Iran (1%) (Ramezani et al., 2015), Hong Kong (1.1%) (Tang et al., 2016) and China (1.3%) (Kim et al., 2015). Other studies, including one in Alexandria, Egypt, have also found a high incidence of OBI (32%) (Helaly et al., 2015). These differences in the OBI rate among patients receiving haemodialysis, and differences in studies reporting conflicting results in the same country, could be related to differences in the prevalence of HBV infection in different countries. The adoption of safety precautions in dialysis units and the implementation of routine immunization programmes are other differences that have been studied for various molecular biological methods for the detection of HBV-DNA (Polaris Observatory Collaborators, 2018).

This study found that the prevalence of T-HBcAb was 47.5% in the 80 patients who tested negative for HBsAg on routine ELISA, which is consistent with a previous report from northeastern Brazil (38%) (Fontenele et al., 2015). Other studies have reported differential prevalence rates of HBcAb in patients receiving haemodialysis in Bushehr province, Iran (6.7%) and in Isfahan, Iran (6.2%) (Mostaghni et al., 2011; Kalantari et al., 2016). These differences could be due to differences in the prevalence of HBcAb in countries. Yemen is categorized as having an intermediate HBV endemicity (Al-Nwany et al., 2021). Most studies with similar results were also conducted in countries with intermediate endemicity for HBV. The highest prevalence rates have been found in countries with moderate or high endemicity for HBV (Zampino et al., 2015). Various serological methods and kits can be used to assess and detect HBV infection. This study found a significant association between HBV-DNA and HBcAb in patients receiving haemodialysis. This result was similar to a study undertaken in Giza, Egypt (Elbahrawy et al., 2015). The results can be explained by the small sample size. Mutated virus cannot be detected with commercially available kits. Differing levels of HBV viraemia during disease between patients could be the reason. The present study did not find an association between positive or negative HBcAb and the following risk factors: duration of dialysis, blood transfusion, surgical history, dental procedure, dialysis outside specified the aims of the study, and family history of HBV infection. Significant relationships were found between HBV-DNA and HBcAb positivity, and between HBV-DNA and HBsAg positivity. These results can be explained by the small size of the study groups, and few studies examining the impact of risk factors in patients receiving haemodialysis.

Study limitations

This study had a few limitations. The patients were all from one governorate, private hospitals were not included, and HBV was the only virus studied due to the high financial cost of the tests.

Conclusions

In conclusion, the prevalence of OBI, based on conventional PCR, was 5% among patients receiving haemodialysis in Sana’a city, Yemen. The prevalence of HBV infection, based on detection of T-HBcAb, in patients receiving haemodialysis in Sana’a city was 47.5%. A significant association was found between T-HBcAb and HBV-DNA. No significant association was found between positive or negative HBcAb and risk factors.

Conflict of interest statement

None declared.

Funding

None.

Ethical approval

The Medical Ethics Committee, Sana’a University, Medical College and Sana’a city health authorities approved the study protocol. Consent
was obtained from all participants, who were informed that participation was voluntary and that they could decline without giving any reason. Feedback was given to the participants at the end of the study.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jiregi.2022.09.004.

References

Abdel-Maksoud NHM, El-Shamy A, Fawry M, Gomaa HHA, Eltarebbili MMA. Hepatitis B variants among Egyptian patients undergoing hemodialysis. Microbiol Immunol 2019;63:77–84.

Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004;11:18–25.

Al-Nwany NT, Ahmad N, Mohammed Nawi A, Hassan MR, Hod R, Baharoon M. Serorelevance of hepatitis B virus infection and its associated factors among blood donors in Yemen. Malays J Med Sci 2021;28:54–63.

Bedewy KML, Ibrahim YN. TT-virus and occult hepatitis B virus infections in Egyptian hemodialysis patients. Egypt J Med Microbiol 2006;15:1–6.

Coppola N, Onorato I, Pisaturo M, Macera M, Sagnelli C, Martini S, et al. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol 2015;21:11931–40.

Dutta S, Chatterjee S, Veer V, Chakrvartty R. Molecular biology of the hepatitis B virus for clinicians. J Clin Exp Hepatol 2012;2:353–65.

El-Ghitany EM, Farghaly AG, Hashish MH. Occult hepatitis B virus infection among hepatitis C virus seropositive and seronegative blood donors in Alexandria, Egypt. Egypt J Public Health Assoc 2013;88:8–13.

Elhbawary A, Alabdouly A, El Moghazy W, Elwassif E, Alashker A, Abdallah AM. Occult hepatitis B virus infection in Egypt. World J Hepatol 2015;7:1671–8.

Fontenele AM, Gainer JB, da Silva ESOG, Cruz Santos MD, Salgado JV, Salgado Filho N, et al. Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil. Hemodial Int 2015;19:353–9.

Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, et al. Occult hepatitis B virus infection: detection and significance. Dig Dis 2010;28:116–25.

Healy GF, El Ghazzawi EF, Shawky SM, Farag FM. Occult hepatitis B virus infection among chronic hemodialysis patients in Alexandria, Egypt. J Infect Public Health 2015;8:562–9.

Kalantari H, Ferdowski F, Yazan M. Prevalence of occult hepatitis B virus infection in hemodialysis patients in Isfahan, Iran. Adv Biomed Res 2016;5:151.

Khour G, Fayyad-Kazan M, Haddad A, Badran B, Tarhini M. Hepatitis B Virus DNA is absent in Lebanese blood donors who are positive for both anti-Hbc and anti-Hbs antibodies. Hepat Mon 2017;17:e44787.

Kim SM, Kim HW, Lee JE, Lee EK, Shin HD, Song BI. (2015). Occult hepatitis B virus infection of hemodialysis patients: a cross-sectional study in a hepatitis B virus-endemic region. Hemodial Int 2015;19:66–71.

Martinez MC, Kok CC, Balentiola C, Robertson P, Rawlinson WD. Investigation of occult hepatitis B virus infection in anti-Hbc positive patients from a liver clinic. PLoS One 2015;10:15.

Mostaghni AA, Soltanian A, Mokhtar M, Japoni S, Mehrabani D. Serorelevance of hepatitis B virus among hemodialysis patients in Bushehr province, southern Iran: HBV serorelevance in hemodialysis patients. Hepat Mon 2011;11:200–2.

Murad EA, Babiker SM, Gasm IS, Rayis DA, Adam I. Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana’a, Yemen. BMC Pregnancy Childbirth 2013;13:127.

Nakamoto S, Kanda T, Nakaseko C, Saida E, Ohwada C, Takeuchi M, et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci 2014;15:2455–67.

Onorato I, Pisaturo M, Camani A, Grimaldi P, Codella AV, Calò F, et al. Risk and prevention of hepatitis B virus reactivation during immunosuppression for non-oncological diseases. J Clin Med 2021;10:5201.

Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3:383–403.

Rameezani A, Aghanadeghi MR, Ahmadi F, Razegei E, Eslamifar A, Banifazl M, et al. Isolated anti-HBC and occult HBV infection in dialysis patients. Nephrur Monol 2015;7:e22674.

Rashid PMA, Salih GF. Identification and genotyping of hepatitis B virus by PCR assay using genotype specific primers. J Clin Virol 2015;69:230.

Sharfi-Mood B, Sanie Moghadam E, Ghasem-Zadeh I, Khorasvi S. Occult hepatitis B virus infection among anti-Hbc only positive individuals in the Southeast of Iran in high prevalence of HBV infection region. Iran Red Cerc Med J 2009;209:90–2.

Song SH, Hwang SG. Occult hepatitis B virus infection: transmission and reactivation. Korean J Gastroenterol 2015;62:148–53.

Squadrone G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol 2014;27:15–19.

Taha SE, El-Hady SA, Ahmed TM, Ahmed EZ. Detection of occult HBV infection by nested PCR assay among chronic hepatitis C patients with and without hepatocellular carcinoma. Egypt J Med Hum Genet 2013;14:453–60.

Tang H-I, Poon CK-Y, Lam BH-S, Lee S-H, Kong L-L, Lee W, et al. Mpl/Jrnulloccult hepatitis B virus infection in a cohort of hemodialysis patients in Hong Kong. Nephrol Dial Transplant 2016;31(Suppl. 1):i542.

Thabt A, Al-Moyed K, Al-Balushi M, Hasson S, Sallam T. Occult hepatitis B virus among chronic liver disease patients in Yemen. Asian Pacif J Trop Dis 2012;2:4–6.

Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol 2015;21:11941–53.